[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Cen et al., 2024 - Google Patents

Azide-modified corrole phosphorus complexes for endoplasmic reticulum-targeted fluorescence bioimaging and effective cancer photodynamic therapy

Cen et al., 2024

Document ID
2951461250745693759
Author
Cen J
Xie Q
Guo G
Gao L
Liao Y
Zhong X
Liu H
Publication year
Publication venue
European Journal of Medicinal Chemistry

External Links

Snippet

Study on corrole photosensitizers (PSs) for photodynamic therapy (PDT) has made remarkable progress. Targeted delivery of PSs is of great significance for enhancing therapeutic efficiency, decreasing the dosage, and reducing systemic toxicity during PDT …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
    • A61K47/48061—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent being a heterocyclic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0073—Rhodium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Similar Documents

Publication Publication Date Title
Shum et al. Luminescent ruthenium (II) polypyridine complexes for a wide variety of biomolecular and cellular applications
Burke et al. Targeting photoinduced DNA destruction by Ru (II) tetraazaphenanthrene in live cells by signal peptide
Lee et al. Recent development of luminescent rhenium (I) tricarbonyl polypyridine complexes as cellular imaging reagents, anticancer drugs, and antibacterial agents
Liu et al. Versatile strategy to generate a rhodamine triplet state as mitochondria-targeting visible-light photosensitizers for efficient photodynamic therapy
Kar et al. Recent advances on organelle specific Ru (II)/Ir (III)/Re (I) based complexes for photodynamic therapy
Renfrew et al. Cobalt (III) chaperone complexes of curcumin: photoreduction, cellular accumulation and light‐selective toxicity towards tumour cells
Karges et al. Polymeric encapsulation of a ruthenium polypyridine complex for tumor targeted one-and two-photon photodynamic therapy
Zhou et al. Endoplasmic reticulum-localized two-photon-absorbing boron dipyrromethenes as advanced photosensitizers for photodynamic therapy
Ferino et al. Photodynamic therapy for ras-driven cancers: Targeting G-quadruplex RNA structures with bifunctional alkyl-modified porphyrins
Karges et al. Polymeric encapsulation of a Ru (II)-based photosensitizer for folate-targeted photodynamic therapy of drug resistant cancers
Sarkar et al. Mixed-ligand cobalt (III) complexes of a naturally occurring coumarin and phenanthroline bases as mitochondria-targeted dual-purpose photochemotherapeutics
Balewski et al. A mini-review: Recent advances in coumarin-metal complexes with biological properties
Lei et al. Mitochondria-targeting properties and photodynamic activities of porphyrin derivatives bearing cationic pendant
Kaulage et al. Novel ruthenium azo-quinoline complexes with enhanced photonuclease activity in human cancer cells
Toubia et al. Synthesis and anticancer activity of gold porphyrin linked to malonate diamine platinum complexes
Sun et al. DNA interaction and photodynamic antitumor activity of transition metal mono-hydroxyl corrole
Bhattacharyya et al. BODIPY-attached zinc (II) complexes of curcumin drug for visible light assisted photo-sensitization, cellular imaging and targeted PDT
Tabrizi et al. New cyclometalated Ir (III) complexes with NCN pincer and meso-phenylcyanamide BODIPY ligands as efficient photodynamic therapy agents
Roy et al. Photocytotoxic 3d-metal scorpionates with a 1, 8-naphthalimide chromophore showing photoinduced DNA and protein cleavage activity
Couto et al. Zinc (II), copper (II) and nickel (II) ions improve the selectivity of tetra-cationic platinum (II) porphyrins in photodynamic therapy and stimulate antioxidant defenses in the metastatic melanoma lineage (A375)
Sojka et al. Locked and loaded: ruthenium (II)-capped cucurbit [n] uril-based rotaxanes with antimetastatic properties
Dias et al. An efficient synthetic access to new uracil-alditols bearing a porphyrin unit and biological assessment in prostate cancer cells
Rovira et al. Exploring Structure–Activity Relationships in Photodynamic Therapy Anticancer Agents Based on Ir (III)-COUPY Conjugates
Deda et al. Correlation of photodynamic activity and singlet oxygen quantum yields in two series of hydrophobic monocationic porphyrins
Wang et al. Self-Assembly of Erlotinib-Platinum (II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy